VIVUS Say Qnexa Obesity Drug Results Are Positive

More research needs to be done with Qnexa before it can be licenced

VIVUS Inc have announced the results of clinical testing done with its new weight loss medication Qnexa.  The mid stage clinical trial shows that the diabetic volunteers who used it ended up with lower blood sugar levels and lost weight. VIVUS explained that those people who used the Qnexa drug had clinically significantly greater reductions in their HbA1c blood sugar levels and lost weight when compared to the people who took part but were given a placebo drug. The clinical testing which involved 130 obese individuals continued for just over one year.

We have written about Qnexa previously at Ukmedix News and progress however has been slow in getting its approval and this is likely because it contains phentermine which is sometimes frowned upon by medical experts because it was once an active ingredient of the drug Fen-phen which was linked to serious heart valve problems.  Qnexa also contains another compound called topiramate that is used to treat people who suffer from migraine seizures.

VIVUS that is researching Qnexa however are positive about the results and their share price rose over two percent on the news. The amount of money being invested in weight loss research and development in America is astronomical as the returns are potentially huge.  Any medication which has a serious impact on obesity would not only massively improve the quality of life for the millions of obese people around the world but also has a significant application in reducing obesity related health care costs. 

More research needs to be done with Qnexa before it can be licenced for Food & Drug Administration approval in America and at Ukmedix News we will be following its progress carefully. Some financial and medical analysts however said that in view of the fact that the FDA is extremely strict and getting regulatory approval is difficult, it may be that this weight loss drug Qnexa will never come to the market.